| Bowlus, Christopher L |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Recruiting | 3 | 251 | Europe, Canada, Japan, US, RoW | Linerixibat | GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited | Cholestasis | 02/27 | 02/27 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd., ChemomAb Ltd | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC |
|
|
| Not yet recruiting | 2 | 87 | US | LB-P8 low-dose, LB-P8 high-dose, Placebo | LISCure Biosciences | Primary Sclerosing Cholangitis (PSC) | 03/28 | 02/29 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis |
|
|
| Active, not recruiting | 1/2 | 42 | US | CNP-104, Placebo | COUR Pharmaceutical Development Company, Inc. | Primary Biliary Cholangitis | 01/26 | 01/26 | | |
| Wagh, Mihir |
| Active, not recruiting | N/A | 1000 | US | AGBS, Allurion Gastric Balloon System (AGBS) | Allurion Technologies | Obesity | 11/24 | 03/25 | | |
NCT04404101: Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies |
|
|
| Recruiting | N/A | 300 | US | 1). EUS-FNA plus MFB, 2). EUS-FNA Alone | University of Colorado, Denver, US Endoscopy | Pancreatic Cyst | 04/25 | 04/25 | | |
| Mark, Tomer |
| Recruiting | 1 | 35 | US | Venetoclax, ABT-199, Abbvie, CC-486 | University of Colorado, Denver, Bristol-Myers Squibb | AML | 03/27 | 03/29 | | |
| Terminated | N/A | 465 | US | clonoSEQ Assay | Adaptive Biotechnologies | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma | 10/23 | 10/23 | | |
| Cho, Steve |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
VENICE, NCT05280366: STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma |
|
|
| Active, not recruiting | N/A | 150 | US, RoW | Streamline Surgical System, iStent Inject W | New World Medical, Inc. | Open Angle Glaucoma | 06/26 | 06/26 | | |
| Lee, Joyce |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Taylor, Matthew |
| Active, not recruiting | 2 | 194 | Europe, US, RoW | ISA101b, Cemiplimab, Placebo | ISA Pharmaceuticals, Regeneron Pharmaceuticals | Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive | 09/24 | 06/25 | | |
NCT05308901: Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma |
|
|
| Active, not recruiting | 2 | 6 | US | Pembrolizumab, Keytruda, Lenvatinib | Providence Health & Services, Merck Sharp & Dohme LLC, Eisai Inc. | Melanoma, Uveal | 12/24 | 06/27 | | |
NCT05200143: Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma |
|
|
| Terminated | 2 | 4 | US | Ipilimumab, Nivolumab, BMS-936558, MDX1106, ONO-4538, Cabozantinib, XL184 | Providence Health & Services, Bristol-Myers Squibb, Exelixis | Refractory Cutaneous Melanoma | 09/23 | 07/24 | | |
NCT05913388: GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 92 | US | GB1211, Pembrolizumab, Keytruda, Placebo | Providence Health & Services, Providence Cancer Center, Providence Cancer Center, Earle A. Chiles Research Institute, Galecto Biotech AB | Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma | 02/28 | 02/30 | | |
| Recruiting | 1/2 | 320 | US, RoW | BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta) | BioAtla, Inc. | NSCLC, Melanoma | 12/25 | 06/26 | | |
| Recruiting | 1/2 | 316 | US | ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA® | Simcha IL-18, Inc., Merck Sharp & Dohme LLC | Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 265 | Europe, US, RoW | EP0031 | Ellipses Pharma | Advanced Solid Tumor | 12/26 | 06/27 | | |
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 91 | US | IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy | Immune-Onc Therapeutics, Regeneron Pharmaceuticals | Solid Tumor, Adult | 04/24 | 05/24 | | |
NCT01107522: Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas |
|
|
| Active, not recruiting | 1 | 100 | US | CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy | Tactical Therapeutics, Inc. | Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas | 01/25 | 01/26 | | |
RIDGE-1, NCT06228924: Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC |
|
|
| Recruiting | 1 | 15 | US | TN-401 | Tenaya Therapeutics, Johns Hopkins University, Mayo Clinic | Arrhythmogenic Right Ventricular Cardiomyopathy | 05/26 | 10/29 | | |
| Recruiting | 1 | 60 | Canada, US | TBio-4101, TIL, autologous, tumor-reactive, T-cell product, Pembrolizumab, Keytruda | Turnstone Biologics, Corp. | Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/24 | 06/25 | | |
NCT03882437: Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B |
|
|
| Active, not recruiting | 1 | 7 | US | RP-A501 | Rocket Pharmaceuticals Inc. | Danon Disease | 03/25 | 03/25 | | |
| Completed | 1 | 91 | US | AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4 | Agenus Inc. | Advanced Cancer | 02/24 | 11/24 | | |
RIDGE, NCT06311708: Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) |
|
|
| Recruiting | N/A | 200 | Europe, US | | Tenaya Therapeutics, University of California, San Francisco, Brigham and Women's Hospital, New York University, University of Colorado, Denver, Johns Hopkins University, The Cleveland Clinic, Mayo Clinic, Medical University of South Carolina, Hopital Louis Pradel, Istituti Clinici Scientifici Maugeri SpA, The Queen Elizabeth Hospital, St George's University Hospitals NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Barts & The London NHS Trust, Skane University Hospital, Centro Cardiologico Monzino, Hôpital Haut-Lévêque, Nantes University Hospital, Pitié-Salpêtrière Hospital, Wuerzburg University Hospital, University Hospital Muenster | Arrhythmogenic Right Ventricular Cardiomyopathy | 03/30 | 07/30 | | |
| Recruiting | N/A | 46 | Europe, US, RoW | No intervention | Rocket Pharmaceuticals Inc. | Danon Disease | 08/26 | 08/26 | | |
| Bessesen, Daniel H |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
| Davis, Shanlee M |
NCT06668805: A Phase 2 Basket Study of Vosoritide in Children with Turner Syndrome, SHOX Deficiency and Noonan Syndrome with an Inadequate Response to Human Growth Hormone |
|
|
| Recruiting | 2 | 72 | US | Vosoritide Injection, Human Growth Hormone | BioMarin Pharmaceutical | Short Stature Homeobox- Containing Gene SHOX Deficiency, Noonan Syndrome, Turner Syndrome | 03/27 | 09/41 | | |
| Erlandson, Kristine |
NCT04495348: Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance |
|
|
| Completed | N/A | 18 | US | Doravirine | University of Colorado, Denver, Gilead Sciences | HIV-1-infection, Weight Gain | 01/23 | 06/23 | | |
| Forman, Lisa |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) |
|
|
| Active, not recruiting | 2 | 24 | US | zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension | Kezar Life Sciences, Inc. | Autoimmune Hepatitis | 02/25 | 08/25 | | |
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC |
|
|
| Not yet recruiting | 2 | 87 | US | LB-P8 low-dose, LB-P8 high-dose, Placebo | LISCure Biosciences | Primary Sclerosing Cholangitis (PSC) | 03/28 | 02/29 | | |
| Ayoub, Walid |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Recruiting | 3 | 251 | Europe, Canada, Japan, US, RoW | Linerixibat | GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited | Cholestasis | 02/27 | 02/27 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Demoruelle, Kristen |
RA-LD, NCT03616158: Investigate the Development and Progression of Lung Disease in Rheumatoid Arthritis Over Time |
|
|
| Recruiting | N/A | 340 | US | | National Jewish Health, Pfizer | Rheumatoid Arthritis, Lung Diseases | 05/23 | 12/24 | | |
| Schatz, Derek |
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 2 | 18 | US | Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone | University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI) | Multiple Myeloma in Relapse | 08/24 | 11/25 | | |
ASTX660-03, NCT05403450: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) |
|
|
| Active, not recruiting | 1/2 | 132 | Europe, US, RoW | Tolinapant, ASTX660, Decitabine + Cedazuridine, ASTX727 | Taiho Oncology, Inc. | Relapsed/Refractory Peripheral T-cell Lymphoma | 12/25 | 12/26 | | |
| Active, not recruiting | 1 | 106 | US | IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven | Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM) | AML With Monocytic Differentiation, CMML | 01/26 | 01/27 | | |
| Recruiting | 1 | 35 | US | Venetoclax, ABT-199, Abbvie, CC-486 | University of Colorado, Denver, Bristol-Myers Squibb | AML | 03/27 | 03/29 | | |
| Terminated | N/A | 465 | US | clonoSEQ Assay | Adaptive Biotechnologies | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma | 10/23 | 10/23 | | |
| Subramanian, Prem |
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study |
|
|
| Active, not recruiting | 4 | 313 | Europe, US | Teprotumumab, TEPEZZA, Placebo, Saline Solution | Amgen | Thyroid Eye Disease | 04/26 | 04/26 | | |
| Active, not recruiting | 3 | 154 | Europe, Canada, US, RoW | Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo | Viridian Therapeutics, Inc., Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/24 | 03/25 | | |
| Ruiz, Monica |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | US, RoW | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Wallace, Elizabeth |
NCT04540445: Utility of Pupillary Metrics in Diagnosis and Management of Concussion in Children |
|
|
| Recruiting | N/A | 130 | US | Pupillary Assessment, NeurOptics PLR-3000, NeurOptics NPi®-200 | Children's Hospital of Orange County, NeurOptics Inc. | Brain Concussion, Reflex, Pupillary, Post-Concussion Syndrome, Brain Injuries, Traumatic | 09/22 | 12/22 | | |
| Stasa, Charles |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc., Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
| Recruiting | 2 | 180 | Europe, Canada, Japan, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Biliary Cholangitis, PBC | 12/25 | 12/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Lengel, Haylie A |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Kuehn, Allison |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | US, RoW | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |
| Active, not recruiting | 2 | 180 | US, RoW | Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent | Zydus Therapeutics Inc. | Nonalcoholic Steatohepatitis, Fibrosis | 07/25 | 07/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Maxwell, Hailey |
NCT04404101: Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies |
|
|
| Recruiting | N/A | 300 | US | 1). EUS-FNA plus MFB, 2). EUS-FNA Alone | University of Colorado, Denver, US Endoscopy | Pancreatic Cyst | 04/25 | 04/25 | | |
| Sreenivasan, Varun |
| Recruiting | N/A | 150 | Europe, Canada, Japan, US, RoW | | argenx | Multifocal Motor Neuropathy | 11/25 | 11/25 | | |
